NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OABI
OmniAb, Inc.
There isn't enough reported data to score OABI yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OABI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Healthy | |
| Unavailable |
OABI's revenue and cash flow are currently healthy, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OABI PE Valuation
OABI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OABI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OABI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OABI on earnings quality, reporting a profit while its opponent remains loss making.
OABI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.34 | +$0.25 |
| Q2 2026 | -$0.36 | +$0.25 |
| Q1 2026 | -$0.46 | +$0.13 |
| Q4 2025 | -$0.57 | +$0.04 |
| Q3 2025 | -$0.59 | +$0.03 |
| Q2 2025 | -$0.61 | +$0.01 |
| Q1 2025 | -$0.59 | +$0.05 |
| Q4 2024 | -$0.61 | -$0.10 |
OABI is still losing money, but less than at its worst: $0.34 per share over the past year, against $0.64 at its worst in early 2024.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OABI on profitability, with a higher operating margin.
OABI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | +78% |
| Q2 2026 | $13.4M | +244% |
| Q1 2026 | $14.4M | +247% |
| Q4 2025 | $8.4M | -22% |
| Q3 2025 | $2.2M | -46% |
| Q2 2025 | $3.9M | -49% |
| Q1 2025 | $4.2M | +9.3% |
| Q4 2024 | $10.8M | +124% |
OABI's revenue is recovering but still below its 2023 peak: $4M last quarter, up 78% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -410% | +400 points |
| Q2 2026 | -49% | +367 points |
| Q1 2026 | -54% | +399 points |
| Q4 2025 | -188% | -41 points |
| Q3 2025 | -810% | -336 points |
| Q2 2025 | -416% | -202 points |
| Q1 2025 | -454% | +140 points |
| Q4 2024 | -147% | +293 points |
OABI's operating margin was −410% last quarter, up 400 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
OABI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +$20.5M |
| Q2 2026 | $2.6M | +$7.9M |
| Q1 2026 | -$5.1M | +$11M |
| Q4 2025 | -$5.7M | -$1.8M |
| Q3 2025 | -$9.9M | -$3.2M |
| Q2 2025 | -$5.3M | +$7.6M |
| Q1 2025 | -$16.1M | +$1.9M |
| Q4 2024 | -$3.9M | +$5.3M |
OABI has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OABI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OABI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +500K shares |
| 1 year | +22% | +23.1M shares |
| 3 years | +30% | +29.8M shares |
OABI has 129M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OABI Net Leverage
OABI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OABI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 86.4 | Overbought |
OABI's weekly RSI is 71 (overbought) and its Stochastic is 86 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OABI PE vs Healthcare Sector
OABI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OABI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.83 | 2.5% above |
| 20 week MA | $3.88 | 28% above |
| 50 week MA | $2.70 | 83% above |
| 100 week MA | $2.45 | 102% above |
| 200 week MA | $3.54 | 40% above |
OABI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OABI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $6.61 | $3.56 | -46% |
| 2023 | $3.56 | $6.17 | +73% |
| 2024 | $6.17 | $3.59 | -42% |
| 2025 | $3.59 | $1.93 | -46% |
| 2026 YTD | $1.93 | $4.95 | +156% |
OABI has the edge over NVO on returns for 2026, with the stronger performance.